|Articles|June 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2001
  • Volume 0
  • Issue 0

Emotion - Biotech Renaissance Man

Author(s)Gil Bashe

The founder of five biotech companies rarely pauses, even to rest. "I can do a lot of work when the rest of my family is sleeping," he reports. "Early in the morning or late at night, there are no phones, so I needn't divert my attention." His affable tone seems contrary to the relentless drive needed to support a lifelong pursuit of excellence, but his achievements speak for themselves.

Articles in this issue

over 25 years ago

Industry Under Investigation

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

For Love of the Game

over 25 years ago

Field of Dreams

over 25 years ago

Workshop: Access Options

over 25 years ago

Emotion - The New Brand Integrator

over 25 years ago

Rx-to-OTC: Unwanted Attention

over 25 years ago

Relocation: Coming to America

over 25 years ago

Stocks: Catching the Market Blues

over 25 years ago

Gathering Light

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.